首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   2230篇
  免费   133篇
  国内免费   8篇
耳鼻咽喉   21篇
儿科学   22篇
妇产科学   54篇
基础医学   338篇
口腔科学   22篇
临床医学   223篇
内科学   624篇
皮肤病学   37篇
神经病学   153篇
特种医学   49篇
外科学   288篇
综合类   24篇
一般理论   1篇
预防医学   126篇
眼科学   24篇
药学   140篇
中国医学   6篇
肿瘤学   219篇
  2023年   35篇
  2022年   14篇
  2021年   72篇
  2020年   65篇
  2019年   52篇
  2018年   84篇
  2017年   43篇
  2016年   49篇
  2015年   68篇
  2014年   94篇
  2013年   108篇
  2012年   165篇
  2011年   163篇
  2010年   94篇
  2009年   69篇
  2008年   139篇
  2007年   143篇
  2006年   122篇
  2005年   133篇
  2004年   115篇
  2003年   89篇
  2002年   90篇
  2001年   28篇
  2000年   22篇
  1999年   22篇
  1998年   9篇
  1997年   13篇
  1996年   10篇
  1995年   7篇
  1993年   9篇
  1992年   16篇
  1991年   12篇
  1990年   16篇
  1989年   20篇
  1988年   15篇
  1987年   12篇
  1986年   11篇
  1985年   10篇
  1981年   6篇
  1980年   8篇
  1979年   11篇
  1978年   9篇
  1977年   8篇
  1976年   8篇
  1975年   7篇
  1974年   7篇
  1972年   9篇
  1970年   12篇
  1969年   6篇
  1967年   7篇
排序方式: 共有2371条查询结果,搜索用时 15 毫秒
1.
2.
Oral and Maxillofacial Surgery - Presently, the functional reconstruction of the tongue in patients after subtotal or total glossectomy with the removal of the oral floor muscles and spearing of...  相似文献   
3.
Preface     
Cancer and Metastasis Reviews -  相似文献   
4.
5.
The activation of oncogenic mitogen-activated protein kinase cascade via mutations in BRAF is often observed in human melanomas. Targeted inhibitors of BRAF (BRAFi), alone or as a part of a combination therapy, offer a significant benefit to such patients. Unfortunately, some cases are initially nonresponsive to these drugs, while others become refractory in the course of treatment, underscoring the need to understand and mitigate the underlying resistance mechanisms. We report that interference with polo-like kinase 3 (PLK3) reduces the tolerance of BRAF-mutant melanoma cells to BRAFi, while increased PLK3 expression has the opposite effect. Accordingly, PLK3 expression correlates with tolerance to BRAFi in a panel of BRAF-mutant cell lines and is elevated in a subset of recurring BRAFi-resistant melanomas. In PLK3-expressing cells, R406, a kinase inhibitor whose targets include PLK3, recapitulates the sensitizing effects of genetic PLK3 inhibitors. The findings support a role for PLK3 as a predictor of BRAFi efficacy and suggest suppression of PLK3 as a way to improve the efficacy of targeted therapy.  相似文献   
6.
Graefe's Archive for Clinical and Experimental Ophthalmology - To investigate the prognostic value of peripheral retinal nonperfusion in patients with diabetic retinopathy using ultra-widefield...  相似文献   
7.
Liver cirrhosis is an important risk factor for hepatocellular carcinoma. The reported annual incidence of HCC is about 3%‐8% in CHC cirrhotic patients. Based on the Cochrane systematic review, there was no clear evidence, on the long‐term clinical effects of DAAs in patients achieving SVR, as regard liver cirrhosis‐related HCC incidence. The aim of the study was to determine the incidence of HCC in chronic hepatitis C patients genotype IV with liver cirrhosis and advanced liver fibrosis after achieving SVR following DAA treatment in a prospective large cohort of HCV patients with long follow‐up. This was a prospective observational cohort study including 2372 CHC patients with advanced liver fibrosis or cirrhosis receiving DAA therapy in outpatient clinics at the Egyptian Liver Research Institute and Hospital since January 2015. Liver fibrosis was assessed using transient elastography. Abdominal ultrasonography and AFP measurement were done at baseline and follow‐up visits every 6 months, in addition to triphasic abdominal MSCT when needed. Patients were followed up after achieving SVR12 for at least 12 months. HCC developed in 109 cases during the follow‐up period (mean 23.60 ± 8.25 months). Overall HCC incidence was 2.338/100 PY, 95% CI = 1.942‐2.814. In patients with cirrhosis, the incidence of HCC was 2.917/100 PY, 95% CI = 2.407‐3.535, while in patients with advanced liver fibrosis the incidence of HCC was 0.664/100 PY, 95% CI = 0.333‐1.326. In conclusion, the incidence of HCC was reduced in chronic hepatitis C genotype 4 patients with liver cirrhosis (F4) and advanced hepatic fibrosis (F3) who achieved SVR following DAA therapy.  相似文献   
8.
OBJECTIVETo determine whether the benefits of dapagliflozin in patients with heart failure and reduced ejection fraction (HFrEF) and type 2 diabetes in the Dapagliflozin And Prevention of Adverse-Outcomes in Heart Failure trial (DAPA-HF) varied by background glucose-lowering therapy (GLT).RESEARCH DESIGN AND METHODSWe examined the effect of study treatment by the use or not of GLT and by GLT classes and combinations. The primary outcome was a composite of worsening heart failure (hospitalization or urgent visit requiring intravenous therapy) or cardiovascular death.RESULTSIn the 2,139 type 2 diabetes patients, the effect of dapagliflozin on the primary outcome was consistent by GLT use or no use (hazard ratio 0.72 [95% CI 0.58–0.88] vs. 0.86 [0.60–1.23]; interaction P = 0.39) and across GLT classes.CONCLUSIONSIn DAPA-HF, dapagliflozin improved outcomes irrespective of use or no use of GLT or by GLT type used in patients with type 2 diabetes and HFrEF.  相似文献   
9.
10.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号